Informed Consent in Clinical Research: What Site Staff and Sponsors Need to Get Right

Informed consent is often incorrectly reduced to simply needing a signature on a form. In reality, it is one of the most misunderstood processes in clinical research, though it can be of the most consequence. A researcher should not treat consent as an endpoint as the regulating bodies, sponsors, and institutional review boards (IRB) won’t. It is viewed as documentation for an ongoing conversation to protect research participants. When that conversation or documentation falls short, it can be one of the most consequential findings in FDA inspection and sponsor audits. 

Understanding informed consent as a process and not a document is crucially important for clinical research coordinators (CRCs), site leadership, and for running ethical, compliant, and audit ready clinical trial sites. 

What Informed Consent in Research Actually Means

Informed consent is the process by which a potential research participant learns the important details and facts about a clinical trial they might enroll in. This includes the trial’s purpose, procedures, risks, benefits, and alternatives for the potential participant. Through this process the potential research participant is free from coercion and undue influence and can voluntarily agree to participate in the trial. 

The consent process is grounded in ethical principles and backed by federal regulations. In the United States the FDA regulates practices related to human subject protections. Internationally, the ICH Good Clinical Practice (GCP) guidelines are an operational standard that most sponsor and sites follow. 

Participant autonomy is the core ethical principle driving informed consent across all clincial trial phases. This means that the participant’s rights are respected, they fully understand what they are agreeing to, are respected, and the participant is allowed to make the decision to participate without pressure. 

The Consent Form Is Not the Consent Process

This straightforward distinction, that the consent form and consent process are not the same, is one that can trip up even the most experienced sites. The Informed Consent Form (ICF) is a required document, but the signatures on the form represent a much longer involved process with participant’s autonomy in mind. The informed consent process should include:

• A private, unhurried conversation between the participant (or their legally authorized representative) and a qualified member of the study team

• Time for the potential participant to ask questions and receive complete, honest answers. Especially about risks and the option to withdraw at any time

• Time for the potential participant to consider the decision. Rather than being asked or pressured to sign during the same visit or after the first mention of the study, whenever feasible

• Confirmation of potential participant’s comprehension of the study and all related information. Not just their willingness to sign, but their willingness to sign with understanding

• Documentation that reflects when, where, and how the conversation happened. This should not just be documentation that the signature was obtained, but the process of informing the potential participant. 

A site can have a technically compliant ICF and still run a deficient consent process if the human conversation behind it was rushed, incomplete, or one-sided. 

Key Elements of a Valid Informed Consent Document

There are specific items that must be listed on a properly constructed ICF. With all documentation it is importat to follow ALCOA-C prniciples for appropriate documentatoin. It is important to note that all regulatory requirements should be confirmed against the most up to date regulatory texts. In general, a proper ICF should communicate the following in language the participant is able to understand:

• The purpose of the study and that is involves research 

• A description of the study procedures and how long the the procedures and the study as a whole will last

• Any reasonably foreseeable risks or discomforts that may result from study participation

• Any expected benefits to the participant or others

• Alternative treatments or procedures, if applicable

• How confidentiality of records for the participants and the study will be maintained

• Compensation and/or medical treatment available if injury occurs

• Contact information for questions about the study, participant rights, or research-related injury

• A clear statement that participation is voluntary and can be withdrawn at any time without penalty

  
  

It is crucial that sites follow proper documentation protocol such as ALCOA-C when documenting the consent process. 

Special Considerations for Vulnerable and Complex Populations

Not every potential participant is able to provide consent on their own. Sites need to prepare for this instance of a potential participant being unable to provide consent under the standard process. Sites will need a documented procedures for these example situations which are not all inclusive:

• Non-English-speaking participants: These conversations typically require a qualified interpreter and fully translated consent documents. Having a family member provide an informal translation is not an accepted alternative in most cases

  
  

• Participants with diminished decision-making capacity: If a potential participant is not able to make decisions on their own behalf, protocols require a legally authorized representative (LAR) to provide consent. The potential participant's assent should still be obtained where possible.

  
  

• Pediatric participants: For pediatric patients, consent is typically obtained from a parent or guardian. Age-appropriate assent from the child themselves may also be required depending on the protocol and IRB requirements.

  
  

• Emergency research settings: Some studies operate under specific regulatory pathways that provide exemption from informed consent. These pathways still carry their own strict documentation and community consultation requirements.

  
  

Sites with broad population ranges should build these scenarios into their staff training. For independent practices entering the clinical research field this helps establish procedures early and limits future training or retraining. 

Re-Consent: Consent Doesn't End at Enrollment

It is also important to recognize that informed consent is not a one-time event. 

During a trial there may be new safety information that emerges, a protocol might be amended in a way that impacts participants, or a revised ICF might be approved by the IRB. In instances such as these sites would be required to re-consent their active study participants. 

This need to re-consent is a common gap that comes up in site operations. This is typically due to deficiencies in tracking which participants need re-consent, when they need it, and documenting how it was done. This documentation can fall through the cracks if this process is not established and standardized. A simple tracking log tied to protocol amendment dates prevents this from becoming a finding during a monitoring visit or audit.

Common Informed Consent Deficiencies Seen in Audits

It is important to understand common findings related to improper informed consent processes. These repeated issues are common across site monitoring visits and FDA inspections:

1. Missing or incomplete documentation of the consent conversation itself (date, time, location, who was present)

2. Outdated ICF versions used after an IRB-approved revision

3. Consent obtained after study procedures began, even by a short window

4. Signatures missing from the participant, the person obtaining consent, or a required witness

5. No documented re-consent following a material protocol amendment

6. Consent rushed during an already-scheduled clinical visit, with no real opportunity for questions or reflection

   
   

Most of these are not knowledge failures but process failures. While not excellent news this is good news because these findings are preventable with the right site training, documentation, and preparedness.

Building a Reliable Consent Process at the Site Level

There are habits and processes that new and established research sites can implement to establish a strong consent process. This includes items such as:

• Standardize the consent environment: Informed consent conversations should happen in a private setting. They should not be done in a hallway or shared exam room. Staff should ensure this is adequate protection time on the schedule for the consent process to ensure privacy throughout.

  
  

• Use a consent checklist: Establish a standard checklist that is tied to the current IRB-approved ICF version. Confirm that the checklist is related to the most recent ICF version before every conversation.

  
  

• Train every team member: Do not train just the principal investigator but anyone who may obtain consent. Ensure this training covers the regulatory requirements and the communication skills. 

  
  

• Document contemporaneously: Notes about the consent conversation should be written at the time it happens. Do not wait till later to write home down to try and reconstruct them.

  
  

• Build re-consent tracking: Make this a standard and have it in your regulatory binder or site management system from day one. This will help reduce stress or potential findings by preventing retrofitting it after an amendment.

  
  

  

  
  

The Bottom Line

Informed consent is an important process that touches on ethics, regulation, and day-to-day clinical research site operations. Treating it as a genuine conversation, supporting it with clear documentation and a consistent process will help protect research participants. It will also help protect data integrity and the site's standing with sponsors and regulators alike.